Skip to Main Content

Author Details

Jack Uetrecht
Leslie Dan Faculty of Pharmacy and Faculty of Medicine, University of Toronto
1980
195
52
PMIDPaper TitleJournal TitlePublished Year
36674761The Role of Myeloperoxidase in Clozapine-Induced Inflammation: A Mechanistic Update for Idiosyncratic Drug-Induced Agranulocytosis.Int J Mol Sci2023
37922508Potential Involvement of Sulfotransferase in the Mechanism of Lamotrigine-induced Skin Rash.Chem Res Toxicol2023
34935985Clozapine Induces an Acute Proinflammatory Response That Is Attenuated by Inhibition of Inflammasome Signaling: Implications for Idiosyncratic Drug-Induced Agranulocytosis.Toxicol Sci2022
35687011Idiosyncratic Drug Reactions: A 35-Year <i>Chemical Research in Toxicology</i> Perspective.Chem Res Toxicol2022
36084709Sulfation of 12-hydroxy-nevirapine by human SULTs and the effects of genetic polymorphisms of SULT1A1 and SULT2A1.Biochem Pharmacol2022
33394045Investigating the Mechanism of Trimethoprim-Induced Skin Rash and Liver Injury.Toxicol Sci2021
33644572Testing Possible Risk Factors for Idiosyncratic Drug-Induced Liver Injury Using an Amodiaquine Mouse Model and Co-treatment with 1-Methyl-d-Tryptophan or Acetaminophen.ACS Omega2021
33639435Severe cutaneous adverse reaction associated with antiseizure medications: Diagnosis, management, and prevention.Epilepsy Behav2021
33617238Liver Injury Caused by Green Tea Extract in PD-1<sup>-/-</sup> Mice: An Impaired Immune Tolerance Model for Idiosyncratic Drug-Induced Liver Injury.Chem Res Toxicol2021
33799477Idiosyncratic Drug-Induced Liver Injury: Mechanistic and Clinical Challenges.Int J Mol Sci2021
34016669The Emerging Role of the Innate Immune Response in Idiosyncratic Drug Reactions.Pharmacol Rev2021
33987428Mechanism of idiosyncratic drug induced liver injury (DILI): unresolved basic issues.Ann Transl Med2021
32768244Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.J Autoimmun2020
33132241Reactive metabolite of gefitinib activates inflammasomes: implications for gefitinib-induced idiosyncratic reaction.J Toxicol Sci2020
30663942Involvement of CCL2/CCR2 macrophage recruitment in amodiaquine-induced liver injury.J Immunotoxicol2019
31324698The 2-Hydroxyiminostilbene Metabolite of Carbamazepine or the Supernatant from Incubation of Hepatocytes with Carbamazepine Activates Inflammasomes: Implications for Carbamazepine-Induced Hypersensitivity Reactions.Drug Metab Dispos2019
31402866Mechanistic Studies of Idiosyncratic DILI: Clinical Implications.Front Pharmacol2019
31307585Mechanisms of idiosyncratic drug-induced liver injury.Adv Pharmacol2019
31251588Rotenone Increases Isoniazid Toxicity but Does Not Cause Significant Liver Injury: Implications for the Hypothesis that Inhibition of the Mitochondrial Electron Transport Chain Is a Common Mechanism of Idiosyncratic Drug-Induced Liver Injury.Chem Res Toxicol2019
30318948The skin as a metabolic and immune-competent organ: Implications for drug-induced skin rash.J Immunotoxicol2019
28865237Dose-dependent acute liver injury with hypersensitivity features in humans due to a novel microsomal prostaglandin E synthase 1 inhibitor.Br J Clin Pharmacol2018
30021844Do In Vitro Assays Predict Drug Candidate Idiosyncratic Drug-Induced Liver Injury Risk?Drug Metab Dispos2018
29938495The Effects of Immune Modulators on Amodiaquine-Induced Liver Injury.Chem Res Toxicol2018
29424579Nevirapine-induced liver lipid-SER inclusions and other ultrastructural aberrations.Ultrastruct Pathol2018
29733743Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury.J Immunotoxicol2018
29087505Editor's Highlight: An Impaired Immune Tolerance Animal Model Distinguishes the Potential of Troglitazone/Pioglitazone and Tolcapone/Entacapone to Cause IDILI.Toxicol Sci2018
27775332How Reactive Metabolites Induce an Immune Response That Sometimes Leads to an Idiosyncratic Drug Reaction.Chem Res Toxicol2017
30873473Immune mechanisms of idiosyncratic drug-induced liver injury.J Clin Transl Res2017
28279082Effects of immunization and checkpoint inhibition on amodiaquine-induced liver injury.J Immunotoxicol2017
28525267Supernatant from Hepatocyte Cultures with Drugs That Cause Idiosyncratic Liver Injury Activates Macrophage Inflammasomes.Chem Res Toxicol2017
26773235Mechanism of isoniazid-induced hepatotoxicity: then and now.Br J Clin Pharmacol2016
27416278Exploring an animal model of amodiaquine-induced liver injury in rats and mice.J Immunotoxicol2016
27415835Deferiprone-induced agranulocytosis: 20 years of clinical observations.Am J Hematol2016
27097313Protein Targets of Isoniazid-Reactive Metabolites in Mouse Liver in Vivo.Chem Res Toxicol2016
24350727Hepatic effects of aminoglutethimide: a model aromatic amine.J Immunotoxicol2015
26529122The Combination of Anti-CTLA-4 and PD1-/- Mice Unmasks the Potential of Isoniazid and Nevirapine To Cause Liver Injury.Chem Res Toxicol2015
26154582The Role of CD8 T Cells in Amodiaquine-Induced Liver Injury in PD1-/- Mice Cotreated with Anti-CTLA-4.Chem Res Toxicol2015
25833746Inhibition of immune tolerance unmasks drug-induced allergic hepatitis.Hepatology2015
25425471Immunization with amodiaquine-modified hepatic proteins prevents amodiaquine-induced liver injury.J Immunotoxicol2015
25424130Current understanding of the mechanisms of idiosyncratic drug-induced agranulocytosis.Expert Opin Drug Metab Toxicol2015
25283142Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients.Hepatology2015
25046026Development of a novel mouse model of amodiaquine-induced liver injury with a delayed onset.J Immunotoxicol2015
23775837Detection of anti-isoniazid and anti-cytochrome P450 antibodies in patients with isoniazid-induced liver failure.Hepatology2014
24968143Clozapine promotes the proliferation of granulocyte progenitors in the bone marrow leading to increased granulopoiesis and neutrophilia in rats.Chem Res Toxicol2014
24968069Effect of clozapine and olanzapine on neutrophil kinetics: implications for drug-induced agranulocytosis.Chem Res Toxicol2014
24771069D-penicillamine-induced granulomatous hepatitis in brown Norway rats.Mol Cell Biochem2014
24786179IgG3 is the dominant subtype of anti-isoniazid antibodies in patients with isoniazid-induced liver failure.Chem Res Toxicol2014
24877608Activation of inflammasomes by agents causing idiosyncratic skin reactions: a possible biomarker.Chem Res Toxicol2014
24564876Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10.Chem Res Toxicol2014
24623063Paradoxical attenuation of autoimmune hepatitis by oral isoniazid in wild-type and N-acetyltransferase-deficient mice.Drug Metab Dispos2014
  • 1 - 50 of 195

Recommended Authors

James Yun
University of Notre Dame
Career Start Year 2008
Number of shared co-authors 1
Kara L Lynch
University of California San Francisco
Career Start Year 2006
Number of shared co-authors 0
Paola Nicoletti
Icahn School of Medicine at Mount Sinai
Career Start Year 2005
Number of shared co-authors 2
Yong Huang
Collegeville
Career Start Year 2004
Number of shared co-authors 0
Eric Gangl
Oncology R&D
Career Start Year 1998
Number of shared co-authors 0
Matthias Schwab
and of Biochemistry and Pharmacy, University of Tuebingen
Career Start Year 1996
Number of shared co-authors 0
Carsten Skarke
University of Pennsylvania.
Career Start Year 1995
Number of shared co-authors 0
Huy Nguyen
The University of Danang-University of Science and Technology
Career Start Year 1993
Number of shared co-authors 0
Saeed A Jortani
University of Louisville
Career Start Year 1991
Number of shared co-authors 0
Thomas Hartung
University of Konstanz
Career Start Year 1991
Number of shared co-authors 1
Cynthia Sung
Health Services and Systems Research, Duke-NUS Medical School
Career Start Year 1990
Number of shared co-authors 2
Christine M Hunt
Duke University Medical Center and Durham Veterans Affairs Health Care System
Career Start Year 1990
Number of shared co-authors 1
Michael Graham Espey
National Cancer Institute, National Institutes of Health
Career Start Year 1990
Number of shared co-authors 0
Timothy A Lewis
National Institute of Allergy and Infectious Diseases, National Institutes of Health
Career Start Year 1990
Number of shared co-authors 0
G R Bond
Hope Africa University
Career Start Year 1989
Number of shared co-authors 0
Francois Pognan
Novartis
Career Start Year 1988
Number of shared co-authors 0
Matthew D Linnik
Lilly Research Laboratories
Career Start Year 1986
Number of shared co-authors 0
Stephen Naylor
ReNeuroGen LLC
Career Start Year 1985
Number of shared co-authors 0
Edward J Otten
Cincinnati Children's Hospital Medical Center
Career Start Year 1982
Number of shared co-authors 0
Rebecca S Gruchalla
University of Texas Southwestern Medical Center
Career Start Year 1981
Number of shared co-authors 1
Lawrence J Lesko
Department of Pharmaceutics, University of Florida
Career Start Year 1979
Number of shared co-authors 0
Dennis P West
Feinberg School of Medicine, Northwestern University
Career Start Year 1977
Number of shared co-authors 0
Michael J Connor
Emory University School of Medicine
Career Start Year 1977
Number of shared co-authors 0
Guillermo Elizondo
Center for Research and Advanced Studies of the National Polytechnic Institute
Career Start Year 1976
Number of shared co-authors 1
Jeffrey A Gelfand
Massachusetts General Hospital
Career Start Year 1974
Number of shared co-authors 0
Garth Powis
PHusis Therapeutics Inc.
Career Start Year 1970
Number of shared co-authors 0
Leslie M Shaw
Perelman School of Medicine, University of Pennsylvania
Career Start Year 1968
Number of shared co-authors 0
Merrill Eric Gershwin
Allergy and Clinical Immunology, University of California at Davis
Career Start Year 1967
Number of shared co-authors 0
Roberto Fanelli
Institut des Biomolecules Max Mousseron (IBMM), UMR-CNRS 7, Universite Montpellier
Career Start Year 1965
Number of shared co-authors 2
Gopal Krishna
ICAR-Central Institute of Fisheries Education
Career Start Year 1964
Number of shared co-authors 0

Collaborators

Marija Popovic
Department of Pharmaceutical Chemistry, Faculty of Pharmacy, University of Belgrade
Co-authored papers 7
B??atrice S??guin
University of Toronto, 101 College Street
Co-authored papers 4
Michael J Rieder
Schulich School of Medicine and Dentistry, University of Western Ontario
Co-authored papers 3
Xujian Li
Wenzhou Institute, University of Chinese Academy of Sciences
Co-authored papers 2
Alastair J J Wood
Vanderbilt University
Co-authored papers 2
Denis M Grant
University of Toronto
Co-authored papers 2
Paul C Boutros
University of California los angeles
Co-authored papers 2
Elizabeth J Phillips
Vanderbilt University Medical Center
Co-authored papers 1
Stephanie R Pacitto
Department of Pharmaceutical Sciences, Faculty of Pharmacy, University of Toronto
Co-authored papers 1
Martha L Dorris
University of Texas Southwestern Medical Center at Dallas
Co-authored papers 1
Grant R Wilkinson
1 Vanderbilt University Medical Center
Co-authored papers 1
Allan B Okey
University of Toronto
Co-authored papers 1
Paul B Watkins
UNC Eshelman School of Pharmacy, The University of North Carolina at Chapel Hill
Co-authored papers 1
Philip David Josephy
Co-authored papers 1
Release 1.2